Back to Search Start Over

Effect of Epidural Dexmedetomidine vs Nalbuphine for Labor Analgesia:#xd; A randomized clinical trial

Authors :
Sanaa M. El Fawal
Reem Hamdy El Kabarity
Nourhan Tarek Fouad Ahmed
Samar M. Abd El Tawab
Source :
Egyptian Journal of Anaesthesia, Vol 38, Iss 1, Pp 373-382 (2022)
Publication Year :
2022
Publisher :
Taylor & Francis Group, 2022.

Abstract

Background The addition of dexmedetomidine or nalbuphine to epidural bupivacaine was tested to decrease labor pain in women undergoing normal delivery.Patients and Methods Sixty-four patients were randomly allocated into 2 groups of 32 parturients, each with consent from the parturient. Groups A and B received a bolus of 12 ml volume consisting of 11 ml of 0.25% bupivacaine and 0.5 μg/ml dexmedetomidine (1 ml volume) through the epidural catheter, then a top-up dose of 6 ml volume consisting of 5 ml of 0.25% bupivacaine and 0.5 μg/ml dexmedetomidine (1 ml volume) was given when the VAS score becomes 4 or more, and a bolus of 12 ml volume consisting of 11 ml of 0.25% bupivacaine and 10 mg nalbuphine (1 ml volume) through the epidural and a top-up dose of 5 ml of 0.25% bupivacaine and 2 mg nalbuphine (1 ml volume) were given, respectively. Assessments included the VAS score, vital data monitoring, duration of stages of labor, APGAR score, and adverse effects.Results Both groups had satisfactory labor analgesia, but those in the dexmedetomidine group had lower pain scores than those in the nalbuphine group, because dexmedetomidine had a faster onset than nalbuphine.Conclusion Epidural dexmedetomidine seems to offer some advantages over epidural nalbuphine. Thus, it can be used safely as an adjuvant to epidural bupivacaine in labor analgesia.

Details

Language :
English
ISSN :
11101849
Volume :
38
Issue :
1
Database :
Directory of Open Access Journals
Journal :
Egyptian Journal of Anaesthesia
Publication Type :
Academic Journal
Accession number :
edsdoj.5eca284655f415ba8d55a5346b118f7
Document Type :
article
Full Text :
https://doi.org/10.1080/11101849.2022.2092300